Navigation Links
Novo Nordisk Inc. Appoints Eddie Li as Vice President, Regulatory Affairs
Date:9/7/2011

PRINCETON, N.J., Sept. 7, 2011 /PRNewswire/ -- Novo Nordisk Inc. announced today that Dr. Eddie Li, has been appointed to join the diabetes leader as Vice President, Regulatory Affairs starting September 12.

Reporting to Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs for North America, Dr. Li brings over 20 years of industry, public sector, and academic experience in the field of regulatory affairs and safety.  He'll be leading Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.

"Eddie has worked within the FDA and other pharmaceutical peers so he brings a wealth of experience to Novo Nordisk.  He comes to us at a critical time in our company as our portfolio continues to grow," said Anne Phillips, M.D., corporate vice president, Clinical, Medical and Regulatory Affairs.  "The regulatory environment is becoming increasingly complex, and Eddie's background suits our needs to have a senior leader as our main point of contact with the FDA."

Originally trained in medicine and toxicology, Dr. Li has an extensive background in the pharmaceutical industry, joining Novo Nordisk from Sanofi, where he most recently was global head of regulatory affairs for one of its largest therapy areas.  He has also worked at Johnson & Johnson and AstraZeneca.  He also served as a staff reviewer at the FDA.

Eddie studied in the Shanghai First Medical College.  He subsequently completed his Ph.D. in Toxicology at the University of Arkansas for Medical Sciences, and also studied in an M.B.A. program at the University of Delaware.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy.  For more information, visit www.novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs
2. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
3. Novo Nordisk A/S: PharmaVitae Profile
4. Video from Novo Nordisk A/S available on thenewsmarket.com: Novo Nordisk Receives Approval for Victoza in China
5. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
6. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
7. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
8. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
9. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
10. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
11. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Greener Hydroponics is now offering a ... frequently used by professional organic farmers and nurseries according to Sales Manager Joe Steele ... fabric pots. Our goal is to offer wholesale level pricing and ultra-fast shipping for ...
(Date:4/28/2016)... Illinois (PRWEB) , ... April ... ... the leading provider of enterprise Data Center Infrastructure Management solutions, announces today ... focuses on feature enhancements in the area of capacity management and optimization, ...
(Date:4/28/2016)... ... ... reminds us that May is National Stroke Awareness Month. According to the Centers for ... the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes occur ... A stroke is when blood flow to the brain is blocked or when a ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th ... Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference and will ...
Breaking Medicine News(10 mins):